These mutations were previously undetected in tumor tissue and are correlated with significantly poorer outcomes: patients with RAS/BRAF mutations at baseline had a shorter progression-free survival (1.8 months vs. 4.9 months, p < 0.001) and overall survival (3.1 months vs. 9.4 months, p = 0.001) compared to those without these mutations [72]. Here, BRAF is linked to neoplasm.